CLBT — Cellebrite DI Income Statement
0.000.00%
Last trade - 00:00
- $2.15bn
- $1.89bn
- $325.11m
- 77
- 21
- 97
- 71
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 20-F | 20-F |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 172 | 195 | 246 | 271 | 325 |
Cost of Revenue | |||||
Gross Profit | 136 | 157 | 204 | 220 | 272 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 173 | 186 | 232 | 270 | 292 |
Operating Profit | -1.52 | 9.22 | 13.8 | 1.04 | 33.2 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 1.42 | 11.4 | 82.3 | 121 | -75.6 |
Provision for Income Taxes | |||||
Net Income After Taxes | -1.88 | 5.78 | 71.4 | 121 | -81.1 |
Net Income Before Extraordinary Items | |||||
Net Income | -1.88 | 5.78 | 71.4 | 121 | -81.1 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -10 | -9.34 | 70.4 | 116 | -81.1 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.053 | -0.05 | 0.428 | 0.616 | -0.426 |
Dividends per Share |